AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36997569 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-121 (oral probiotic formulation)
Number of subjects: 15
Study 36997569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 36997766 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious coping
Number of subjects: 119
Study 36997766 — intervention group
Group type: EXPERIMENTAL
Intervention: Racism-related coping
Number of subjects: 119
Study 36997766 — intervention group
Group type: EXPERIMENTAL
Intervention: Gendered racial microaggressions (GRMs)
Number of subjects: 119
Study 36997799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nivolumab (50 mg) and intravenous nivolumab (240 mg) every 2 weeks
Number of subjects: 25
Study 36997799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal nivolumab (5, 10, 20, and 50 mg)
Number of subjects: 25
Study 36997822 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus GG)
Number of subjects: 34
Study 36997822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 36997856 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS (Clinical Frailty Scale)
Number of subjects: 453
Study 36997856 — intervention group
Group type: EXPERIMENTAL
Intervention: CFS-MDT (Clinical Frailty Scale from Multidisciplinary Team)
Number of subjects: 453
Study 36997936 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention including text messages and Fitbit activity tracker
Number of subjects: 340
Study 36997936 — intervention group
Group type: COMPARATOR
Intervention: Active control arm with Fitbit activity tracker
Number of subjects: 340
Study 36998024 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Connections programme (FC: ED-PD)
Number of subjects: 0
Study 36998024 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual optimised (TAU-O)
Number of subjects: 0
Study 36998047 — intervention group
Group type: EXPERIMENTAL
Intervention: PRiVENT intervention
Number of subjects: 40
Study 36998047 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 40
Study 36998061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuning in to Kids for Kindergarten Teachers (TIK-KT)
Number of subjects: 22
Study 36998155 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR, 60% of habitual sleep)
Number of subjects: 14
Study 36998155 — intervention group
Group type: COMPARATOR
Intervention: Habitual Sleep (HS, 100% normal sleep)
Number of subjects: 14
Study 36998155 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal test following both HS and SR
Number of subjects: 14
Study 36998220 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention group (n=36)
Number of subjects: 105
Study 36998220 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention group (n=32)
Number of subjects: 105
Study 36998220 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=37)
Number of subjects: 105
Study 36998225 — intervention group
Group type: EXPERIMENTAL
Intervention: CCRT (pelvic external-beam radiotherapy + cisplatin or carboplatin every week for 5 cycles + brachytherapy)
Number of subjects: 452
Study 36998225 — intervention group
Group type: COMPARATOR
Intervention: Open/minimally invasive pelvic and para-aortic lymph node dissection followed by CCRT
Number of subjects: 452
Study 36998287 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle intervention with patients' own doctor present in audiovisual content
Number of subjects: 132
Study 36998287 — intervention group
Group type: COMPARATOR
Intervention: Control group (e-counseling)
Number of subjects: 132
Study 36998617 — intervention group
Group type: EXPERIMENTAL
Intervention: High oral loading dose of cholecalciferol (vitamin D)
Number of subjects: 0
Study 36998617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36998625 — intervention group
Group type: EXPERIMENTAL
Intervention: inMind mobile application for stress reduction, which includes modules for meditation, cognitive approach, and relaxation sounds.
Number of subjects: 0
Study 36998625 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 0
Study 36999039 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (IM to IP injections): 10 patients received three vaccines IM biweekly, followed by three vaccines IP biweekly.
Number of subjects: 20
Study 36999039 — intervention group
Group type: COMPARATOR
Intervention: Group B (IP to IM injections): 10 patients received IP vaccines first, followed by IM under a similar vaccination schedule.
Number of subjects: 20
Study 36999039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received the Bcl-XL-peptide-CAF vaccine.
Number of subjects: 20
Study 36999039 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 20
Study 36999231 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 1304
Study 36999231 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 1304
Study 36999231 — intervention group
Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 1304
Study 36999409 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dual antiplatelet therapy (DAPT) for one month
Number of subjects: 0
Study 36999409 — intervention group
Group type: COMPARATOR
Intervention: Standard dual antiplatelet therapy (DAPT) for 12 months
Number of subjects: 0
Study 36999528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose n-3 PUFA (1840 mg eicosapentaenoic acid and 1520 mg docosahexaenoic acid)
Number of subjects: 34
Study 36999528 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 34
Study 36999533 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (1200 mg intravenously Q2W)
Number of subjects: 159
Study 36999619 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 1364
Study 36999619 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 1364
Study 36999619 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 1364
Study 36999619 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 1364
Study 36999805 — intervention group
Group type: COMPARATOR
Intervention: Preoperative 4QTAP block
Number of subjects: 81
Study 36999805 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 4QTAP block and postoperative NETOIMS
Number of subjects: 81
Study 36999805 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia
Number of subjects: 81
Study 36999814 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge Eating Disorder (BED) patients
Number of subjects: 98
Study 36999814 — intervention group
Group type: COMPARATOR
Intervention: Healthy, normal-weight individuals
Number of subjects: 98
Study 36999819 — intervention group
Group type: EXPERIMENTAL
Intervention: O2matic oxygen treatment for 24 hours
Number of subjects: 0
Study 36999819 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen treatment for 24 hours
Number of subjects: 0
Study 36999821 — intervention group
Group type: EXPERIMENTAL
Intervention: MetAAA trial patients
Number of subjects: 77
Study 36999821 — intervention group
Group type: COMPARATOR
Intervention: AAA patients under regular surveillance
Number of subjects: 77
Study 36999825 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for conditional survival after esophagectomy
Number of subjects: 1585
Study 36999830 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (radio)
Number of subjects: 192
Study 36999830 — intervention group
Group type: COMPARATOR
Intervention: Nonradiotherapy (nonradio)
Number of subjects: 192
Study 36999981 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg once daily
Number of subjects: 0
Study 36999981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36999999 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced DW MRI
Number of subjects: 26
Study 36999999 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced DW MRI
Number of subjects: 26
Study 37000164 — intervention group
Group type: EXPERIMENTAL
Intervention: Eganelisib monotherapy (10-60 mg)
Number of subjects: 219
Study 37000164 — intervention group
Group type: EXPERIMENTAL
Intervention: Eganelisib in combination with nivolumab (20-40 mg)
Number of subjects: 219
Study 37000164 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 219
Study 37000207 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT-based TOMOSTEOp algorithm
Number of subjects: 0
Study 37000214 — intervention group
Group type: EXPERIMENTAL
Intervention: Garadacimab (700 mg) plus standard of care (SOC)
Number of subjects: 61
Study 37000214 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care (SOC)
Number of subjects: 61
Study 37000218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sled technique (ST)
Number of subjects: 31
Study 37000245 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk factor treatment programme in a specialized, protocolized, nurse-led outpatient clinic
Number of subjects: 150
Study 37000245 — intervention group
Group type: COMPARATOR
Intervention: Standard care by cardiologists before ablation
Number of subjects: 150
Study 37000245 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk factor treatment programme
Number of subjects: 150
Study 37000245 — intervention group
Group type: COMPARATOR
Intervention: Standard care by cardiologists
Number of subjects: 150
Study 37000264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib with Topotecan (400 mg daily)
Number of subjects: 61
Study 37000310 — intervention group
Group type: EXPERIMENTAL
Intervention: SpilleFri (therapist-guided internet-based treatment program)
Number of subjects: 24
Study 37000389 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 247
Study 37000389 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic Hepatitis (AH)
Number of subjects: 247
Study 37000389 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic Cirrhosis (AC)
Number of subjects: 247
Study 37000389 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic Fatty Liver (AFL)
Number of subjects: 247
Study 37000390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 0
Study 37000390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 0
Study 37000390 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 0
Study 37000390 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide 1 mg
Number of subjects: 0
Study 37000390 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 0
Study 37000448 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 212
Study 37000448 — intervention group
Group type: COMPARATOR
Intervention: Safety control intervention
Number of subjects: 212
Study 37000452 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC plus disulfiram (400 mg daily) and copper (2.5 mg daily)
Number of subjects: 88
Study 37000452 — intervention group
Group type: COMPARATOR
Intervention: SOC alkylating chemotherapy alone
Number of subjects: 88
Study 37000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention developed through cocreative partnerships and managerial support.
Number of subjects: 0
Study 37000508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention evaluation in a randomized controlled trial setting.
Number of subjects: 0
Study 37000515 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive communication model
Number of subjects: 82
Study 37000515 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care
Number of subjects: 82
Study 37000706 — intervention group
Group type: EXPERIMENTAL
Intervention: IBH-PC program implementation
Number of subjects: 8
Study 37000706 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning Stage of IBH-PC program
Number of subjects: 8
Study 37000706 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation Stage of IBH-PC program
Number of subjects: 8
Study 37000942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam+metronidazole
Number of subjects: 91
Study 37000942 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 91
Study 37000976 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Vivity intraocular lens targeted for slight myopia (-0.50 diopters) in the nondominant eye
Number of subjects: 31
Study 37000976 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ Vivity intraocular lens with monovision
Number of subjects: 31
Study 37000976 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual disturbances reported
Number of subjects: 31
Study 37000976 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 31
Study 37001058 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalized stigma assessment among adults with comorbid HIV and MDD
Number of subjects: 339
Study 37001128 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend household visits (Sunday shifts)
Number of subjects: 62455
Study 37001128 — intervention group
Group type: COMPARATOR
Intervention: Traditional weekday shifts
Number of subjects: 62455
Study 37001128 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekend household visits (Saturday shifts)
Number of subjects: 62455
Study 37001280 — intervention group
Group type: EXPERIMENTAL
Intervention: Philani Intervention Program (PIP)
Number of subjects: 0
Study 37001280 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study 37001428 — intervention group
Group type: EXPERIMENTAL
Intervention: MHBC intervention
Number of subjects: 2531
Study 37001428 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2531
Study 37001446 — intervention group
Group type: EXPERIMENTAL
Intervention: DKN-01 monotherapy
Number of subjects: 0
Study 37001446 — intervention group
Group type: EXPERIMENTAL
Intervention: DKN-01 in combination with paclitaxel
Number of subjects: 0
Study 37001534 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis (25 mg/kg per day, four equal doses of 6.25 mg/kg) plus best supportive care
Number of subjects: 372
Study 37001534 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care only
Number of subjects: 372
Study 37001534 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis
Number of subjects: 372
Study 37001534 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 372
Study 37001590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratrial mean 25(OH)D ≥ 40 ng/mL
Number of subjects: 2362
Study 37001590 — intervention group
Group type: COMPARATOR
Intervention: Lower concentrations of intratrial mean 25(OH)D
Number of subjects: 2362
Study 37001762 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR system
Number of subjects: 81
Study 37001762 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 81
Study 37001859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab plus chemotherapy (350 mg every 3 weeks for up to 108 weeks)
Number of subjects: 466
Study 37001859 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (placebo plus chemotherapy)
Number of subjects: 466
Study 37001911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 50 mg
Number of subjects: 0
Study 37001911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg
Number of subjects: 0
Study 37001911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirikizumab 600 mg
Number of subjects: 0
Study 37001911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37001917 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBI + treatment as usual (TAU) for 12 weeks, n=450
Number of subjects: 750
Study 37001917 — intervention group
Group type: COMPARATOR
Intervention: TAU alone for 12 weeks, n=300
Number of subjects: 750
Study 37001917 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBI + TAU
Number of subjects: 750
Study 37001971 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapalumab with background glucocorticoids
Number of subjects: 14
Study 37001971 — intervention group
Group type: EXPERIMENTAL
Intervention: Emapalumab
Number of subjects: 14
Study 37002053 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-home intervention (HHI)
Number of subjects: 130
Study 37002053 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention (TI)
Number of subjects: 130
Study 37002119 — intervention group
Group type: EXPERIMENTAL
Intervention: XRT prophylaxis
Number of subjects: 277
Study 37002119 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 277
Study 37002119 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin prophylaxis
Number of subjects: 277
Study 37002379 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 408
Study 37002379 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 408
Study 37002379 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA
Number of subjects: 408
Study 37002379 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and PSA
Number of subjects: 408
Study 37002654 — intervention group
Group type: EXPERIMENTAL
Intervention: Vupanorsen (PF-07285557), dosage and duration not specified
Number of subjects: 0
Study 37002654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37003098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 287
Study 37003273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 8246
Study 37003273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Number of subjects: 8246
Study 37003273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8246
Study 37003278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis (80 mg subcutaneous once per month)
Number of subjects: 120
Study 37003278 — intervention group
Group type: COMPARATOR
Intervention: On-demand clotting factor concentrates
Number of subjects: 120
Study 37003278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis
Number of subjects: 120
Study 37003287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis (80 mg subcutaneous once a month)
Number of subjects: 57
Study 37003287 — intervention group
Group type: COMPARATOR
Intervention: Bypassing agents on-demand
Number of subjects: 57
Study 37003287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis
Number of subjects: 57
Study 37003355 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol-budesonide 180/160 μg
Number of subjects: 1001
Study 37003355 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol-budesonide 180/80 μg
Number of subjects: 1001
Study 37003355 — intervention group
Group type: COMPARATOR
Intervention: Albuterol 180 μg
Number of subjects: 1001
Study 37003355 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 160 μg
Number of subjects: 1001
Study 37003355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1001
Study 37003356 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundance of Malassezia globosa at baseline
Number of subjects: 301
Study 37003356 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative abundance of Malassezia globosa at yellow zone episode
Number of subjects: 301
Study 37003458 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematically aligned TKA
Number of subjects: 62
Study 37003458 — intervention group
Group type: COMPARATOR
Intervention: Mechanically aligned TKA
Number of subjects: 62
Study 37003540 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP/NX (buprenorphine/naloxone)
Number of subjects: 272
Study 37003540 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 272
Study 37003908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (150,000 IU) in Group D
Number of subjects: 28
Study 37003908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D supplementation) in Group C
Number of subjects: 28
Study 37003908 — intervention group
Group type: EXPERIMENTAL
Intervention: Final measurements in Group D
Number of subjects: 28
Study 37003986 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline sirolimus-coated balloon (cSCB)
Number of subjects: 0
Study 37003986 — intervention group
Group type: COMPARATOR
Intervention: iopromide-paclitaxel coated balloon (iPCB)
Number of subjects: 0
Study 37003997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 65
Study 37003997 — intervention group
Group type: COMPARATOR
Intervention: High-resolution computed tomography (HRCT)
Number of subjects: 65
Study 37004046 — intervention group
Group type: COMPARATOR
Intervention: Lenvatinib
Number of subjects: 0
Study 37004046 — intervention group
Group type: COMPARATOR
Intervention: Sintilimab plus bevacizumab
Number of subjects: 0
Study 37004046 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab plus bevacizumab
Number of subjects: 0
Study 37004046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 37004049 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial blood flow (MBF) at rest and adenosine-stress, and perfusion reserve (MPR)
Number of subjects: 205
Study 37004049 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular volume fraction (ECV)
Number of subjects: 205
Study 37004049 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular dysfunction
Number of subjects: 205
Study 37004049 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse fibrosis
Number of subjects: 205
Study 37004068 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic clinical decision support system (CDSS) implemented at three pilot sites.
Number of subjects: 13
Study 37004078 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled biliary interventions (therapeutic ERC) every 8 weeks for 6 months
Number of subjects: 104
Study 37004078 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 104